Recent Updates
Recently added Catalysts

Primary Erythromelalgia: one US-listed biotech with a clinical-stage programme

Neurology & PsychiatryUncontestedData as of 2026-09-04

Competitors1in the clinic
Median market cap$2.4Buniverse median $1.20B
Allocated capital$342M$2.4B competing
Phase 3 or filed00 mid, 1 early
Pure plays0this indication only
Capital rank229/299crowding rank 232

Primary Erythromelalgia is uncontested. Biohaven (BHVN) is the only US-listed developer in the $100M to $20B band running a clinical programme here, with BHV-7000 in phase 1.

There is no public comparable to price it against. BHVN spreads its $2.4B market cap across 7 indications, so $342M of it is allocated here.

Nothing here has reached Phase 3: 0 programmes in mid stage and 1 in early stage, so the field is still several years from a first approval.

$342M of allocated capital sits in Primary Erythromelalgia, ranking it 229th of 299 indications by the money committed to it.

Companies developing drugs for Primary Erythromelalgia 1

TickerCompanyLead assetPhaseTrialsMarket capPure playIndicationsNext catalyst
BHVNBiohavenBHV-7000Phase 11$2.4BNo7 23 Oct 2026

Sorted by phase, then by market capitalisation. Ticker links open the company profile.

Why Primary Erythromelalgia counts as uncontested

Uncontested. One US-listed developer in the size band is running a clinical programme here, so there is no public comparable to price it against.

The map splits indications on two folds: six or more competitors counts as crowded, and a median company above $1.20B counts as richly priced. Primary Erythromelalgia has one competitor and a median of $2.4B.

Neurology & Psychiatry

Neurology & Psychiatry holds $120B of the map's capital, 17.9% of the total, spread across 46 indications and 58 companies. 19 of those indications have more than one company competing.

See every Neurology & Psychiatry indication on the map

Related indications in Neurology & Psychiatry

Cervical Spinal Cord Injury1 company · $278M · median $278MUncontestedOsteoarthritis Knee Pain1 company · $265M · median $1.1BUncontestedAcute Postoperative Pain1 company · $265M · median $1.1BUncontestedPostoperative Pain1 company · $265M · median $1.1BUncontestedMajor Depressive Episode1 company · $426M · median $1.3BUncontestedMigraine1 company · $218M · median $436MUncontestedAcute Ischemic Stroke2 companies · $486M · median $1.3BConcentrated betPsychosis in Alzheimer's Disease1 company · $187M · median $560MUncontested

Primary Erythromelalgia pipeline questions

Which biotech companies are developing drugs for Primary Erythromelalgia?

Biohaven (BHVN, BHV-7000, Phase 1). Those are the 1 US-listed developer in the $100M to $20B market cap band with a clinical-stage programme in Primary Erythromelalgia.

How advanced is the Primary Erythromelalgia pipeline?

Of the 1 clinical-stage programme in Primary Erythromelalgia, 0 are in Phase 3 or filed, 0 are in mid-stage development and 1 is in early-stage development.

Is anyone else developing a drug for Primary Erythromelalgia?

No. BHVN is the only US-listed company in the $100M to $20B market cap band with a clinical-stage programme in Primary Erythromelalgia, which is why the indication is classified as uncontested.

When is the next Primary Erythromelalgia catalyst?

The next dated catalyst in Primary Erythromelalgia is BHVN on 23 Oct 2026. 1 dated event across the field fall in the next 12 months.

How this page is built

  • Universe is US-listed drug developers with a $100M to $20B market capitalisation, identified by SEC SIC code 2833, 2834 or 2836 or by a pharmaceutical or biotechnology industry classification, less a reviewed exclusion list of contract research organisations, device and diagnostics makers and diversified generics manufacturers.
  • An asset attributed to three or more different companies is treated as shared standard of care rather than any one company’s programme and excluded. Pembrolizumab alone appears under 21 tickers in raw trial data.
  • A programme counts only where at least one industry-sponsored trial supports it, so investigator-initiated academic studies of third-party drugs are excluded.

Allocated capital divides each company’s market capitalisation evenly across the indications it is running clinical programmes in, so every dollar of the universe is counted exactly once. Total market capitalisation competing counts a company in each of its indications and therefore sums to more than the universe.

Third-party market size estimates are not used anywhere on this page. Approved incumbents are excluded from competitor counts, and companies above $20B are outside the universe by construction.

Back to the disease map